Biofrontera Inc.
BFRIHealthcare|Medical - Pharmaceuticals|US
$0.83
+0.02 (+2.50%)
Tangible Book / Share
$0.26
Cash / Share
$0.36
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06745999 Cryotherapy in Combination With Red Light PDT for Actinic Keratosis of Full Face | Actinic Keratoses | P4 | Active | 40 | RCT, Open-label | Ameluz 10% Topical Gel |
| NCT03573401 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | Superficial Basal Cell Carcinoma | P3 | Active | 187 | RCT, Double-blind | — |
| NCT05359419 Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities | Skin Neoplasms | P4 | Unknown | 20 | RCT, Single-blind | — |
| NCT05662202 Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp | Actinic Keratoses | P3 | Completed | 172 | RCT, Double-blind | — |
| NCT02799082 Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. | Actinic Keratosis | P3 | Completed | 122 | RCT, Double-blind | Vehicle, BF-200 ALA |
| NCT01966120 Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) | Actinic Keratosis | P3 | Completed | 87 | RCT, Double-blind | BF-200 ALA gel, Placebo to BF-200 ALA gel |
| NCT02144077 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | Basal Cell Carcinoma (BCC) | P3 | Completed | 281 | RCT, Double-blind | BF-200 ALA, methyl-aminolevulinate |
| NCT02799069 Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy | Actinic Keratosis | P3 | Completed | 571 | RCT, Single-blind | BF-200 ALA, MAL Cream, Vehicle |
| NCT06577311 Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | Cutaneous Squamous Cell Carcinoma | P2 | Unknown | 20 | Open-label | — |
| NCT06027619 Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses | Actinic Keratosis | P2 | Completed | 30 | RCT, Open-label | Topical aminolevulinate (10% ALA gel) |
| NCT05080764 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults | Acne Vulgaris | P2 | Completed | 120 | RCT, Double-blind | — |
| NCT02799030 A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis | Actinic Keratosis | P2 | Completed | 105 | RCT, Double-blind | BF-200 ALA 1%, BF-200 ALA 3%, BF-200 ALA 10% |
| NCT07053852 Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage | Actinic Keratoses, Photodamage | P1 | Completed | 10 | Open-label | Ameluz |
| NCT05060237 Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp | Actinic Keratosis, Keratosis, Actinic | P1 | Completed | 112 | Open-label | — |
| NCT04319159 Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK) | Actinic Keratoses | P1 | Completed | 48 | Open-label | — |